Source comparison
CJC-1295 vs Tesamorelin: Research Applications Comparison
Half-Life & Dosing 6–8 days; weekly SC injection 26–38 minutes; daily SC injection CJC-1295 wins for logistics; Tesamorelin wins for pulsatile control FDA Approval Status None (investigational only) FDA-approved for HIV lipodystrophy (2010) Tesamorelin require
This comparison does not assign a generated winner or score.
- Half-Life & Dosing
- 6–8 days; weekly SC injection
- 26–38 minutes; daily SC injection
- CJC-1295 wins for logistics; Tesamorelin wins for pulsatile control
- FDA Approval Status
- None (investigational only)
- FDA-approved for HIV lipodystrophy (2010)
- Tesamorelin required for institutional compliance in many settings
- Visceral Fat Reduction Evidence
- No Phase III data; limited VAT-specific studies
- 15.2% mean VAT reduction in Phase III trials (JAMA)
- Tesamorelin has definitive clinical evidence; CJC-1295 does not
- GH Secretion Pattern
- Sustained low-amplitude pulses over days
- Acute physiological pulses with rapid clearance
- CJC-1295 for cumulative anabolic studies; Tesamorelin for acute GH response models
- Side Effect Profile
- Mild (flushing, headache) in limited trials; long-term unknown
- Injection site reactions (20–35%), hyperglycemia (10%) well-documented
- Tesamorelin has robust safety data; CJC-1295 lacks Phase III monitoring
- Cost (Research Supply)
- Lower (research-grade sourcing)
- Higher (FDA-approved clinical product ~$3,000/month)
- CJC-1295 more accessible for budget-limited protocols